Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Ten years after first being identified with breast most cancers, Cynthia Malaran stated she nonetheless faces some unintended effects from therapy, however...
Early outcomes from the section 2 LEGEND trial confirmed that detalimogene coraplasmid (previously EG-70) confirmed encouraging outcomes for sufferers with high-risk, Bacillus...
Tracy Milgram-Posner established BRCAStrong in 2015 after greater than a decade of navigating her BRCA2 genetic mutation alone. Having undergone two benign...
